May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI

Jun 24, 2026 | FDA Approves Gilead's Trodelvy for Front-Line TNBC; Lilly's $1.9B Abbisko Deal

Gilead's Trodelvy wins front-line triple-negative breast cancer approval — and the stock barely moves. Lilly expands its Abbisko partnership to $1.9B, Novartis pays $105M upfront to Antares for undruggable cancer targets, and three ADC stories in two days force a class-level reckoning. pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Trodelvy, sacituzumab govitecan, Gilead, TNBC, triple-negative breast cancer, FDA approval, Eli Lilly, Abbisko Therapeutics, Novartis, Antares Therapeutics, ADC, antibody-drug conjugate, Pfizer, Ibrance, Ionis, triglycerides, Ollin, Vabysmo, ADC Therapeutics, Zynlonta, HHS, pelacarsen, BioNTech, Lilly, Roche

Jun 23, 2026 | Pfizer Seagen ADC Fails in Lung Cancer Phase 3; CMS Settles Opzelura Classification

Pfizer's sigvotatug vedotin disappoints in Phase 3 NSCLC — another blow to the $43B Seagen deal. Plus CMS settles with Incyte on Opzelura classification, Sangamo Therapeutics closes after 30 years, and Moderna's flu vaccine wins unanimous FDA panel support. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Pfizer, Seagen, sigvotatug vedotin, ADC, antibody-drug conjugate, non-small cell lung cancer, NSCLC, Incyte, Opzelura, Jakafi, ruxolitinib, CMS, Medicare Part D, Sangamo Therapeutics, zinc-finger nuclease, gene editing, Eli Lilly, Astellas, Moderna, mFlusiva, flu vaccine, Regenxbio, UniQure, gene therapy, Makary, Genentech, Novartis, Xolair, Braftovi, encorafenib, 340B, Sanofi, Houman Ashrafian, Bionyra, Osanni Bio, Lilly, AstraZeneca, Merck

Jun 22, 2026 | AbbVie's $10.9B Apogee Buy Targets Dupixent; 1st Solid Tumor CAR-T Approved in China

AbbVie bets $10.9B on Apogee Therapeutics to challenge Dupixent — its biggest deal since Allergan. Plus: the first CAR-T approved for a solid tumor clears in China, Merck's $10.8B Prometheus IBD bet pays off with a Phase 3 win, and HHS clinical trial reforms target China.   Visit www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, AbbVie, Apogee Therapeutics, zumilokibart, Dupixent, Regeneron, Sanofi, CARsgen, CAR-T, Claudin 18.2, solid tumor, gastric cancer, Merck, Prometheus Biosciences, IBD, Keytruda, HHS, RFK Jr, clinical trial reform, Moderna, mFlusiva, Alnylam, Pfizer, Kardigan, MacroGenics, TZIELD, Bionyra, cAMPfield, WuXi Biologics, Novartis, pelacarsen, UniQure, AMT-130, Novo Nordisk, ransomware, BMS

Jun 19, 2026 | US Probes Germany Drug Pricing; Moderna Flu Vaccine Wins Unanimous FDA Panel

US government opens formal probe into Germany's drug pricing reforms, escalating transatlantic pharma trade tensions. Kardigan IPO raises $400M and pops 31%. Moderna flu vaccine gets unanimous FDA advisory panel support ahead of Aug 5 PDUFA. Jazz and AbCellera strike $4.1B T cell engager collaboration. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Germany drug pricing, US trade probe, Moderna flu vaccine, mFlusiva, Kardigan IPO, Jazz Pharmaceuticals, AbCellera, T cell engagers, Pfizer CFO Dave Denton, Eli Lilly, 4E Therapeutics, Edgewise Biosciences, HCM, Biogen, RayThera, Traws Pharma, tivoxavir marboxil, Merck Capvaxive, Treasury China biotech, cAMPfield, Vedana Therapeutics, Spot Bio, Innoviva, Lyndra, Sanofi, Aurobindo, Lannett, Pfizer, Lilly, Merck, Moderna

Jun 18, 2026 | Moderna mFlusiva Wins Unanimous VRBPAC Vote; NovoCure TRIDENT Fails in GBM

Moderna's mRNA flu vaccine gets unanimous FDA panel backing — PDUFA August 5. NovoCure's TRIDENT trial misses overall survival in glioblastoma; stock drops ~18%. Biogen acquires immunology startup RayThera for up to $1B; Kardigan IPO raises $400M. Visit us at www.thepharmacloseput.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Moderna, mFlusiva, MRNA, VRBPAC, mRNA flu vaccine, NovoCure, NVCR, TRIDENT, glioblastoma, TTFields, Biogen, BIIB, RayThera, immunology, Pfizer, PFE, CFO, Kardigan, IPO, cAMPfield, Legend Biotech, LEGN, Carvykti, Eli Lilly, 4E Therapeutics, Merck, Capvaxive, pneumococcal vaccine, Innoviva, Lyndra, Aurobindo, Lannett, FTC, Treasury, China biotech, Lilly, GSK, Sanofi